NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Did she really say Nivo?
Checkmate 498 is Nivo.
But the neo adjuvant v adjuvant ICI study was Keytruda in resectable rGBM.
I'm just loathe for NWBO to combo up with any ICI in either L or Direct, until baseline efficacy and safety for DCVax as a monotherapy is firmly established. If you don't do that first, it may put you at a big disadvantage for ever after.

At least in the proposed resectable recurrent trial, one arm is just DCVax only, the other being DCVax plus Nivo.

The Nivo will only be a post-surgery adjuvant, which is where Keytruda did badly.
I just don't really see what it will prove.
Other than DCVax will do better!
I definitely don't think it will help BMY move forward at all in GBM. But that bit's OK by me.
When I keep reading patient reports of GBM sufferers having awful side-effects from Keytruda, I just think they should think long and hard before committing to combos.